Cargando…

ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data

ICI 182,780 (Fulvestrant™) is the first in a new class of novel, steroidal, ’pure‘ antioestrogens – the oestrogen receptor (ER) down-regulators. Its unique mode of action and the absence of partial agonist activity make it a candidate for the treatment of advanced breast cancer in both pre- and post...

Descripción completa

Detalles Bibliográficos
Autor principal:	Robertson, J F R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2001
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375169/ https://www.ncbi.nlm.nih.gov/pubmed/11900210 http://dx.doi.org/10.1054/bjoc.2001.1982

Ejemplares similares

Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines
por: Woode, Denzel R., et al.
Publicado: (2012)

ICI 182,780 has agonistic effects and synergizes with estradiol-17 beta in fish liver, but not in testis
por: Pinto, Patrícia IS, et al.
Publicado: (2006)

Gonadal steroids differentially modulate neurotoxicity of HIV and cocaine: testosterone and ICI 182,780 sensitive mechanism
por: Kendall, Sherie L, et al.
Publicado: (2005)

A transcriptomics model of estrogen action in the ovine fetal hypothalamus: evidence for estrogenic effects of ICI 182,780
por: Rabaglino, Maria Belen, et al.
Publicado: (2018)

ICI 182,780 Attenuates Selective Upregulation of Uterine Artery Cystathionine β-Synthase Expression in Rat Pregnancy
por: Bai, Jin, et al.
Publicado: (2023)

Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells
por: Okubo, S, et al.
Publicado: (2004)

17β-Estradiol and ICI182,780 Differentially Regulate STAT5 Isoforms in Female Mammary Epithelium, With Distinct Outcomes
por: Jallow, Fatou, et al.
Publicado: (2018)

The antiestrogen ICI 182,780 decreases the expression of estrogen receptor-alpha but has no effect on estrogen receptor-beta and androgen receptor in rat efferent ductules
por: Oliveira, Cleida A, et al.
Publicado: (2003)

Effects of ICI 182,780, an ERα and ERβ antagonist, and G-1, a GPER agonist, on autophagy in breast cancer cells
por: Muler, Mari Luminosa, et al.
Publicado: (2020)

The antiestrogen ICI 182,780 induces early effects on the adult male mouse reproductive tract and long-term decreased fertility without testicular atrophy
por: Cho, Hyun Wook, et al.
Publicado: (2003)

Reduction of post injury neointima formation due to 17β-estradiol and phytoestrogen treatment is not influenced by the pure synthetic estrogen receptor antagonist ICI 182,780 in vitro
por: Finking, Gerald, et al.
Publicado: (2002)

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.
por: Howell, A., et al.
Publicado: (1996)

The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling
por: Martin, L-A, et al.
Publicado: (2005)

Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182(R)-6
por: Jensen, B L, et al.
Publicado: (1999)

Effects of ICI 182780 on estrogen receptor expression, fluid absorption and sperm motility in the epididymis of the bonnet monkey
por: Shayu, Deshpande, et al.
Publicado: (2005)

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
por: Osborne, C K, et al.
Publicado: (2004)

The effects of estrogen, its antagonist ICI 182, 780, and interferon-tau on the expression of estrogen receptors and integrin alphaV beta 3 on cycle day 16 in bovine endometrium
por: Kimmins, Sarah, et al.
Publicado: (2003)

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.
por: DeFriend, D. J., et al.
Publicado: (1994)

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers
por: Addo, S, et al.
Publicado: (2002)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474
por: Cole, M. P., et al.
Publicado: (1971)

Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1
por: Hutcheson, Iain R, et al.
Publicado: (2011)

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2019)

Oestrogens and oestrogen receptors in prostate cancer
por: Kowalska, Karolina, et al.
Publicado: (2016)

Model of the VAX-11/780
Publicado: (1977)

Nikon D780 For Dummies
por: Sahlin, Doug
Publicado: (2020)

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
por: Pancholi, Sunil, et al.
Publicado: (2020)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

Of Oestrogens and Sperm: A Review of the Roles of Oestrogens and Oestrogen Receptors in Male Reproduction
por: Dostalova, Pavla, et al.
Publicado: (2017)

OLYMP - Evaluation of multi-dimensional data on VAX 11/780
por: Egloff, R
Publicado: (1982)

Oestrogen receptor: a stable phenotype in breast cancer.
por: Robertson, J. F.
Publicado: (1996)

Plasma oestrogens and oestrogen receptors in breast cancer patients.
por: Mason, R. C., et al.
Publicado: (1985)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Response in post-menopausal patients on ICI 118630.
por: Robertson, J. F., et al.
Publicado: (1987)

Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
por: Blancas, I., et al.
Publicado: (2021)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Possible permanent down regulation of oestrogen receptor expression during fetal life and breast cancer risk
por: Lawson, J S, et al.
Publicado: (1999)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

Cannot write session to /tmp/vufind_sessions/sess_lk9a0fupd4khubtsknsna9l059